Compounds of formula (I): ##STR00001## wherein R.sup.1 represents optionally substituted C.sub.4-12 alkyl, optionally substituted C.sub.2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH.sub.2, O, S, SO, SO.sub.2, NR.sup.4, OCR.sup.4R.sup.5, CR.sup.4R.sup.5O, or Z, R.sup.1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR.sup.3 or N(OR.sup.8)COR.sup.9; R.sup.2 represents SO.sub.2R.sup.10 or SO.sub.2NR.sup.10R.sup.11; R.sup.3 represents OR.sup.6, NR.sup.6R.sup.7 or NR.sup.6OH; R.sup.4 and R.sup.5 each independently represents H, C.sub.1-6 alkyl or C.sub.1-4 alkylaryl; R.sup.6 and R.sup.7 each independently represents H, C.sub.1-6 alkyl, or C.sub.1-6 alkyl substituted with one or more heteroaryl groups, or R.sup.6 and R.sup.7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R.sup.8 and R.sup.9 each independently represents H or C.sub.1-6 alkyl; R.sup.10 and R.sup.11 each independently represents H or C.sub.1-6 alkyl; and and physiologically functional derivatives thereof, with the exception of N-(ethoxycarbonyl)-N-[4-(1H-tetrazol-1-yl)phenyl]glycine, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metalloproteinase enzymes (MMPs) are described.

 
Web www.patentalert.com

< Methods for producing cyclic benzamidine derivatives

> Therapy control based on the rate of change of intracardiac impedance

~ 00434